<DOC>
	<DOCNO>NCT01517347</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation ( HSCT ) one best , sometimes , option treatment leukemia . However , relapse rate still key question influence overall survival transplantation , even standard risk leukemia.There good evidence natural killer cell T regulatory cell , expand stimulate application IL-2 , could mediate protection GvHD maintain graft anti-tumor activity positive side effect . Meanwhile , find previous pilot study low-dose IL-2 subcutaneous administration 100 day prolonged period could safe effective strategy prevent relapse acute lymphoblastic malignancy patient high risk recurrence unmanipulated allo-HSCT . The study hypothesis : Prevention relapse use low dose IL-2 follow hematopoietic stem cell transplantation patient standard risk acute leukemia - reduce relapse rate - improve survival</brief_summary>
	<brief_title>Efficiency Study Low Dose IL-2 Prevent Relapse Standard Risk Leukemia After Transplantation</brief_title>
	<detailed_description>Standard risk patient 15 year old ( except Ph+ ALL , AML ( 8 ; 21 ) T-ALL ) undergone unmanipulated blood marrow transplantation follow day 60 post-transplantation randomize treat group ( low dose IL-2 treatment ) control group ( without intervention post-transplantation ) . The end point safety clinical immunologic response.Following time 24 month . Primary Outcome Measures : *To determine feasibility efficacy administer 6 course subcutaneous IL-2 patient population . [ Time Frame : 2 year ] Secondary Outcome Measures : *To ass immunologic impact ultra-low dose subcutaneous IL-2 patient transplantation [ Time Frame : 2 year ] Estimated Enrollment:360 Study Start Date : Jan 2012 Estimated Study Completion Date : Jan 2016 Intervention Details Description : *Drug : Interleukin-2 Dose vary depend upon participant enters trial : Given daily injection skin 8 week . Detailed Description : - Patients receive low dose interleukin-2 ( Daily 1×106 IU per square meter body-surface area ) day 60 unmanipulated blood marrow transplantation . Interleukin-2 treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . - Participants see periodically receive IL-2 . Physical exams blood test perform weekly first two week every week completion 6 course therapy . Eligibility Ages Eligible Study:15 Years old Genders Eligible Study : Both Accepts Healthy Volunteers : No Criteria Inclusion Criteria : - Standard risk Recipients allogeneic stem cell transplantation myeloablative conditioning regimens - Standard risk Recipients : CR1 CR 2 AML/ALL transplantation - Ph+ ALL，AML ( 8 ; 21 ) T-ALL except - Patients least 60 day post-transplantation - Bone marrow monitoring still Complete Remission ( CR ) minor residual disease ( MRD ) negative - 15 year age old - No serious infection Exclusion Criteria : - Exposure clinical trial prior enrollment - Active malignant disease relapse - Active , uncontrolled infection - Inability comply IL-2 treatment regimen</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Standard risk Recipients ( CR1 CR 2 AML/ALL transplantation except Ph+ ALL TALL ) allogeneic stem cell transplantation myeloablative conditioning regimens Standard risk Recipients : CR1 CR 2 AML/ALL transplantation Ph+ ALL , AML ( 8 ; 21 ) TALL except Patients least 60 day posttransplantation Bone marrow monitoring still Complete Remission ( CR ) minor residual disease ( MRD ) negative 15 year age old No serious infection Exposure clinical trial prior enrollment Active malignant disease relapse Active , uncontrolled infection Inability comply IL2 treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IL2</keyword>
	<keyword>relapse</keyword>
	<keyword>GVHD</keyword>
	<keyword>survival</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>MRD</keyword>
	<keyword>CR</keyword>
</DOC>